MedImpact is not requiring patients currently taking Humira to switch, and all three products are on a preferred tier. MedImpact Healthcare Systems is providing access to two Humira biosimilars: ...
Natalizumab (Tysabri) and ocrelizumab (Ocrevus) are options if other drugs don't work for you. Natalizumab prevents immune cells from getting to your brain and spinal cord, where they can damage ...
Beginning in 2025, Express Scripts will favor biosimilars of Humira, including its own private-label version. Beginning in 2025, Express Scripts will remove Humira (adalimumab) from its commercial ...